Literature DB >> 29651130

Targeting the tumour stroma to improve cancer therapy.

Kenneth C Valkenburg1, Amber E de Groot2,3, Kenneth J Pienta2,3.   

Abstract

Cancers are not composed merely of cancer cells alone; instead, they are complex 'ecosystems' comprising many different cell types and noncellular factors. The tumour stroma is a critical component of the tumour microenvironment, where it has crucial roles in tumour initiation, progression, and metastasis. Most anticancer therapies target cancer cells specifically, but the tumour stroma can promote the resistance of cancer cells to such therapies, eventually resulting in fatal disease. Therefore, novel treatment strategies should combine anticancer and antistromal agents. Herein, we provide an overview of the advances in understanding the complex cancer cell-tumour stroma interactions and discuss how this knowledge can result in more effective therapeutic strategies, which might ultimately improve patient outcomes.

Entities:  

Mesh:

Year:  2018        PMID: 29651130      PMCID: PMC5960434          DOI: 10.1038/s41571-018-0007-1

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


  351 in total

Review 1.  Metastasis to bone: causes, consequences and therapeutic opportunities.

Authors:  Gregory R Mundy
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

Review 2.  Prognostic relevance of cancer-associated fibroblasts in human cancer.

Authors:  Janna Paulsson; Patrick Micke
Journal:  Semin Cancer Biol       Date:  2014-02-19       Impact factor: 15.707

Review 3.  Fibroblast activation protein-α: a key modulator of the microenvironment in multiple pathologies.

Authors:  Thomas Kelly; Yan Huang; Avis E Simms; Anna Mazur
Journal:  Int Rev Cell Mol Biol       Date:  2012       Impact factor: 6.813

4.  A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer.

Authors:  Oren Levy; W Nathaniel Brennen; Edward Han; David Marc Rosen; Juliet Musabeyezu; Helia Safaee; Sudhir Ranganath; Jessica Ngai; Martina Heinelt; Yuka Milton; Hao Wang; Sachin H Bhagchandani; Nitin Joshi; Neil Bhowmick; Samuel R Denmeade; John T Isaacs; Jeffrey M Karp
Journal:  Biomaterials       Date:  2016-03-17       Impact factor: 12.479

5.  Beta1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts.

Authors:  Catherine C Park; Hui J Zhang; Evelyn S Yao; Chong J Park; Mina J Bissell
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

6.  Matrix rigidity regulates a switch between TGF-β1-induced apoptosis and epithelial-mesenchymal transition.

Authors:  Jennifer L Leight; Michele A Wozniak; Sophia Chen; Michelle L Lynch; Christopher S Chen
Journal:  Mol Biol Cell       Date:  2012-01-11       Impact factor: 4.138

7.  Cancer-associated fibroblasts from human NSCLC survive ablative doses of radiation but their invasive capacity is reduced.

Authors:  Turid Hellevik; Ingvild Pettersen; Vivian Berg; Jan Olof Winberg; Bjørn T Moe; Kristian Bartnes; Ruth H Paulssen; Lill-Tove Busund; Roy Bremnes; Anthony Chalmers; Iñigo Martinez-Zubiaurre
Journal:  Radiat Oncol       Date:  2012-04-13       Impact factor: 3.481

8.  Mesenchymal precursor cells in the blood of normal individuals.

Authors:  N J Zvaifler; L Marinova-Mutafchieva; G Adams; C J Edwards; J Moss; J A Burger; R N Maini
Journal:  Arthritis Res       Date:  2000-08-31

9.  Stromal disrupting effects of nab-paclitaxel in pancreatic cancer.

Authors:  R Alvarez; M Musteanu; E Garcia-Garcia; P P Lopez-Casas; D Megias; C Guerra; M Muñoz; Y Quijano; A Cubillo; J Rodriguez-Pascual; C Plaza; E de Vicente; S Prados; S Tabernero; M Barbacid; F Lopez-Rios; M Hidalgo
Journal:  Br J Cancer       Date:  2013-08-01       Impact factor: 7.640

10.  Collagen prolyl hydroxylases are essential for breast cancer metastasis.

Authors:  Daniele M Gilkes; Pallavi Chaturvedi; Saumendra Bajpai; Carmen C Wong; Hong Wei; Stephen Pitcairn; Maimon E Hubbi; Denis Wirtz; Gregg L Semenza
Journal:  Cancer Res       Date:  2013-03-28       Impact factor: 12.701

View more
  246 in total

Review 1.  Tumor-resident adenosine-producing mesenchymal stem cells as a potential target for cancer treatment.

Authors:  Samaneh Arab; Akram Alizadeh; Samira Asgharzade
Journal:  Clin Exp Med       Date:  2021-01-23       Impact factor: 3.984

2.  Nano-puerarin regulates tumor microenvironment and facilitates chemo- and immunotherapy in murine triple negative breast cancer model.

Authors:  Huan Xu; Mengying Hu; Mengrui Liu; Sai An; Kaiyun Guan; Menglin Wang; Lei Li; Jing Zhang; Jun Li; Leaf Huang
Journal:  Biomaterials       Date:  2020-01-17       Impact factor: 12.479

Review 3.  Navigating CAR-T cells through the solid-tumour microenvironment.

Authors:  Andrew J Hou; Laurence C Chen; Yvonne Y Chen
Journal:  Nat Rev Drug Discov       Date:  2021-05-10       Impact factor: 84.694

4.  T-Cell Deletion of MyD88 Connects IL17 and IκBζ to RAS Oncogenesis.

Authors:  Christophe Cataisson; Rosalba Salcedo; Aleksandra M Michalowski; Mary Klosterman; Shruti Naik; Luowei Li; Michelle J Pan; Amalia Sweet; Jin-Qiu Chen; Laurie G Kostecka; Megan Karwan; Loretta Smith; Ren-Ming Dai; C Andrew Stewart; Lyudmila Lyakh; Wang-Ting Hsieh; Asra Khan; Howard Yang; Maxwell Lee; Giorgio Trinchieri; Stuart H Yuspa
Journal:  Mol Cancer Res       Date:  2019-06-04       Impact factor: 5.852

5.  An Overview of Advances in Cell-Based Cancer Immunotherapies Based on the Multiple Immune-Cancer Cell Interactions.

Authors:  Jialing Zhang; Stephan S Späth; Sherman M Weissman; Samuel G Katz
Journal:  Methods Mol Biol       Date:  2020

Review 6.  Cancer-associated fibroblasts: how do they contribute to metastasis?

Authors:  Mei Qi Kwa; Kate M Herum; Cord Brakebusch
Journal:  Clin Exp Metastasis       Date:  2019-03-07       Impact factor: 5.150

7.  Cancer-associated stroma significantly contributes to the mesenchymal subtype signature of serous ovarian cancer.

Authors:  Qing Zhang; Chen Wang; William A Cliby
Journal:  Gynecol Oncol       Date:  2018-11-15       Impact factor: 5.482

8.  Correlation Analysis of Histopathology and Proteogenomics Data for Breast Cancer.

Authors:  Xiaohui Zhan; Jun Cheng; Zhi Huang; Zhi Han; Bryan Helm; Xiaowen Liu; Jie Zhang; Tian-Fu Wang; Dong Ni; Kun Huang
Journal:  Mol Cell Proteomics       Date:  2019-07-08       Impact factor: 5.911

9.  High-background parenchymal enhancement in the contralateral breast is an imaging biomarker for favorable prognosis in patients with triple-negative breast cancer treated with chemotherapy.

Authors:  Chuanhui Xu; Jinhui Yu; Feifei Wu; Xuemei Li; Dongmin Hu; Guiming Chen; Gang Wu
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

10.  TGFβ and activin A in the tumor microenvironment in colorectal cancer.

Authors:  Jasmin Zessner-Spitzenberg; Alexandra L Thomas; Nancy L Krett; Barbara Jung
Journal:  Gene Rep       Date:  2019-09-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.